T. Rowe Price Investment Management, Inc. Janux Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 972,691 shares of JANX stock, worth $28.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
972,691Holding current value
$28.5 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
183Shares Held
54.9MCall Options Held
598KPut Options Held
212K-
Ra Capital Management, L.P. Boston, MA11.2MShares$328 Million4.7% of portfolio
-
Janus Henderson Group PLC London, X04.7MShares$138 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$85.5 Million2.3% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.78MShares$81.3 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.42MShares$70.8 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.22B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...